Navigation Links
Creabilis Awarded Prestigious European Commission FP7 Grant to Further Develop its LSE 'Topical-by-Design' Technology
Date:4/23/2013

LUXEMBOURG, April 23, 2013 /PRNewswire/ --

Creabilis SA, a late clinical stage European biotechnology company specialising in the development of treatments in dermatology, for inflammation and pain, today announces that it has been awarded a prestigious European Union Framework Programme 7 (FP7) grant in the 'Health: Systems Medicine' work programme theme. The €1.98m FP7 grant will be used to develop the next generation of Creabilis' 'topical-by-design' pre-clinical candidates to complement its existing clinical portfolio. The candidates will be developed using Creabilis' proprietary Low Systemic Exposure (LSE) technology.

Creabilis' LSE technology creates novel drugs that combine high efficacy with a favourable safety profile to be delivered topically. LSE generates innovative molecules with unique physico-chemical and pharmacological characteristics, combining high local concentration with low systemic absorption. This technology has already been clinically validated through CT327, Creabilis' lead compound that is currently in late stage clinical development for diseases of dermatology.

FP7 is the European Union's main instrument for supporting innovative research in Europe, and has two main strategic objectives:

  • to strengthen the scientific and technological base of European industry
  • to encourage its international competitiveness, while promoting research that supports EU policies

The FP7 grant has been awarded on the basis of a highly competitive, two-stage, peer-review process, and the award is a validation of our LSE technology.

Creabilis will be leading a pan-European consortium to help develop the next generation of LSE candidates using a novel systems biology and network pharmacology approach. The FP7 project combines Creabilis' experience and expertise with that of Serichim in Italy, TNO and TNO-Triskelion in the Netherlands, and Professor Andrew Hopkins from the University of Dundee in the UK.

This combined experience and expertise of this high quality consortium will help to generate and bring to preclinical development the next generation of Creabilis molecules optimised for topical treatment of inflammatory and neuroinflammatory diseases.

Dr Eliot Forster , CEO of Creabilis, said: "Creabilis is proud to have been one of the select companies to receive this prestigious award, and it is delightful to have won additional funding to further advance our LSE technology and the work of our scientific team in Italy. We very much look forward to working with the excellent members of the consortium to deliver this project and I am grateful for the support of the EU in this endeavour."

Dr Silvio Traversa , CSO of Creabilis and FP7 Project Coordinator, said: "Over the last eight years we have seen our LSE technology mature and deliver valuable products that are progressing through clinical development in disease areas of significant unmet medical need. This FP7 grant recognises the potential of LSE technology, and the value of our accomplishments in guiding research to achieve clinical stage assets. It is another important validation of the work of our scientific team here in Italy and Creabilis' approach as a whole."

About Creabilis SA

Creabilis is a clinical-stage European biotechnology company creating innovative new drugs to tackle unmet medical needs in dermatology, inflammation and pain. Bringing together world class drug development capabilities and a rich scientific heritage, Creabilis is uniquely positioned to transform the treatment of its target diseases.

Creabilis' lead product is CT327, a novel topically applied TrkA kinase inhibitor developed using the Company's Low Systemic Exposure (LSE) technology. CT327 is currently in late stage clinical development for diseases of dermatology. CT340 is a potent kinase inhibitor under development for the treatment of pain.

Creabilis is backed by some of the most highly respected life sciences investors including Sofinnova Partners, Neomed and Abbott Biotech Ventures, Inc (now AbbVie Biotech Ventures).

Creabilis FP7 Project - Further Information

The full title of the FP7 project is 'LSE-LSE technology approach to generate innovative kinase inhibitor drugs'. The project number is 305272.

 

For further information please contact:

Creabilis
Eliot Forster
eforster@creabilis-sa.com
Creabilis SA
15 rue Edward Steichen
L-2540 Luxembourg

Citigate Dewe Rogerson
Chris Gardner or Nina Enegren
Tel: +44-(0)-20-7282-1050
E-mail: nina.enegren@citigatedr.co.uk


'/>"/>
SOURCE Creabilis SA
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Combat Medical Systems Awarded $86 Million DOD Contract
2. Remedium Technologies Inc. Awarded $500,000 Phase II NSF SBIR Grant to Test Sprayable Foam for Stopping Traumatic Bleeding
3. CCS Medical Awarded Medicare Contract
4. GE alliance awarded contract to design new plant-based manufacturing facility in Brazil
5. Hadasit Bio-Holdings Flagship Portfolio Company Enlivex Awarded Orphan Drug Status for ApoCell Treatment by the FDA
6. Pharmaceutical Executive Magazines 2013 Drug "Brand of the Year" Awarded to Leading Merck Diabetes Drug Januvia
7. Romark Laboratories Awarded Contract For Late-Stage Development Of New Influenza Drug
8. MEDICOMP Medical Awarded GSA Schedule, Will Supply VA Hospitals
9. Grant Awarded to Study Novel Therapies for Muco-Obstructive Diseases Includes Studies on Cempras Solithromycin (CEM-101) in a Cystic Fibrosis Anti-inflammatory Model
10. Metabolic Solutions Development Company Awarded Funding by The Michael J. Fox Foundation
11. Kalyspo Awarded Best of Ann Arbor SPARK Boot Camp
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... 2016 Research and Markets has announced ... in the USA"  report to their offering.  ,     (Logo: ... the current Positron Emission Tomography (PET) scanner and cyclotron ... market. Along with the current known number of PET ... , the report also contains a detailed breakdown of ...
(Date:5/5/2016)... 2016 Research and ... Thalassaemia Market and Competitive Landscape Highlights - ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ) ... Competitive Landscape Highlights - 2016, provides comprehensive ... Thalassaemia market valuations and forecast, Thalassaemia products ...
(Date:5/4/2016)... for an upgrade. There are many medical recorders on the market but none like ... DVMAXX HD  offers unparalleled connectivity and functionality.  Ampronix  is a renowned authorized reseller of ... technology.  Photo - http://photos.prnewswire.com/prnh/20160503/363416 ... ... ...
Breaking Medicine Technology:
(Date:5/6/2016)... ... May 06, 2016 , ... The Price Agency in Birmingham, ... and assist the people of their local community. The agency pledges to select ... leaders. Their desire is to bring awareness to important local causes with fundraising ...
(Date:5/6/2016)... , ... May 06, 2016 , ... ... are scheduled to provide a unique keynote address at the 2016 Learning ... inspirational stories of five community college students. Their stories—of complicated family issues, financial ...
(Date:5/6/2016)... ... May 06, 2016 , ... Bluvault ( ... implementation service offering for global clients of Coupa ( Coupa Software ) and ... Integration Service is a key component in the suite of innovative implementation services ...
(Date:5/6/2016)... OR (PRWEB) , ... May 06, 2016 , ... Logically, ... In other seasons, when the weather is too cold, dry or hot, water on ... eyes can actually absorb moisture from the surrounding air. There’s only one problem, according ...
(Date:5/6/2016)... Atlanta (PRWEB) , ... May 06, 2016 , ... From ... provider Presence Technology will share its insights on managing Customers Engagement at ... , At SpeechTek 2016, Presence Technology will deliver a Presentation on “5 ...
Breaking Medicine News(10 mins):